Marksans Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	10,613	6,341	4,958	4,033	3,824	2,064
Short-Term Investments	623.69	3,567	2,094	2,710	3,328	1,399
Trading Asset Securities	-	-	7.42	269.94	5.4	4.35
Cash & Short-Term Investments	11,236	9,909	7,060	7,013	7,158	3,467
Cash Growth	68.39%	40.36%	0.67%	-2.03%	106.47%	63.19%
Accounts Receivable	7,574	6,446	5,400	4,532	4,168	3,948
Other Receivables	52.77	141.63	144.04	106.62	48.5	43.7
Receivables	7,627	6,587	5,544	4,638	4,217	3,991
Inventory	9,957	9,723	8,455	6,179	4,847	4,244
Prepaid Expenses	-	368.88	302.63	251.26	198.04	159.83
Other Current Assets	1,303	639.61	679.24	543.05	332.57	149.34
Total Current Assets	30,123	27,227	22,041	18,625	16,753	12,012
Property, Plant & Equipment	10,592	9,407	8,954	6,811	3,869	3,423
Long-Term Investments	-	0.1	0.1	1.68	-	-
Goodwill	1,026	452.56	409.28	394.99	384.89	300.25
Other Intangible Assets	1,560	1,168	727.32	647.62	707.97	585.69
Long-Term Deferred Tax Assets	49.33	129.65	-	-	-	38.57
Other Long-Term Assets	245.51	224.97	264.32	329.41	189.13	41.62
Total Assets	43,596	38,609	32,396	26,810	21,904	16,401

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Accounts Payable	3,930	3,369	3,057	2,683	2,306	2,001
Accrued Expenses	3.37	600.89	644.31	442.56	220.96	131.01
Short-Term Debt	290.41	295.91	230.85	290.91	415.88	362.92
Current Portion of Long-Term Debt	-	-	-	-	-	50
Current Portion of Leases	494.65	436.58	354.92	249.51	156.68	280.52
Current Income Taxes Payable	290.66	415.83	299.41	199.08	252.78	173.27
Other Current Liabilities	994.28	152.6	186.91	33.66	57.59	563.67
Total Current Liabilities	6,003	5,271	4,773	3,898	3,410	3,562
Long-Term Leases	3,861	2,701	2,633	1,900	656.89	414.34
Pension & Post-Retirement Benefits	-	47.12	49.47	38.96	23.22	15.73
Long-Term Deferred Tax Liabilities	29.15	50.87	36.62	106.2	153.86	176.21
Other Long-Term Liabilities	29.89	12.03	9.73	6.63	9.3	2.83
Total Liabilities	9,923	8,082	7,503	5,950	4,253	4,171

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Common Stock	453.16	453.16	453.16	453.16	453.16	409.31
Additional Paid-In Capital	-	5,045	5,045	5,045	5,045	1,732
Retained Earnings	-	21,184	17,358	13,827	10,913	8,230
Comprehensive Income & Other	32,870	3,549	1,813	1,326	1,040	1,651
Total Common Equity	33,323	30,232	24,669	20,651	17,452	12,023
Minority Interest	349.47	295.24	224.7	208.52	199.1	207.01
Shareholders' Equity	33,673	30,527	24,894	20,859	17,651	12,230
Total Liabilities & Equity	43,596	38,609	32,396	26,810	21,904	16,401

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Total Debt	4,646	3,434	3,219	2,441	1,229	1,108
Net Cash (Debt)	6,590	6,475	3,841	4,572	5,929	2,359
Net Cash Growth	96.60%	68.59%	-16.00%	-22.88%	151.30%	36.10%
Net Cash Per Share	14.55	14.29	8.48	10.09	14.27	5.76
Filing Date Shares Outstanding	452.92	453.16	453.16	453.16	453.16	409.31
Total Common Shares Outstanding	452.92	453.16	453.16	453.16	453.16	409.31
Working Capital	24,120	21,957	17,268	14,726	13,343	8,450
Book Value Per Share	73.57	66.71	54.44	45.57	38.51	29.37
Tangible Book Value	30,737	28,611	23,533	19,608	16,359	11,137
Tangible Book Value Per Share	67.86	63.14	51.93	43.27	36.10	27.21
Land	-	5.82	5.31	5.18	5.1	4.67
Buildings	-	3,121	2,815	2,287	1,633	1,511
Machinery	-	6,506	5,701	4,445	3,355	3,038
Construction In Progress	-	147.82	90	53.81	72.46	6.95
Leasehold Improvements	-	142.64	116.61	105.64	-	-